ALVO ALVO
Company Profile ↓Company Overview
ALVO (ALVO) is a publicly traded company listed on with a market capitalization of $1.26B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 91.8% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $586.32M (+19.7% YoY); net profit $27.92M.
- Trailing 12 Months Year-on-year growth — revenue +19.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 91.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 91.85% |
| 1 Year: | 19.74% |
Stock Price Performance
| 1 Year: | -57.61% |
| 6 Months: | -27.83% |
| 3 Months: | +7.43% |
| 1 Month: | +7.74% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)56.09 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 91.8% over 5 years.
CONS
- Trading 58.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 132.76M | 173.24M | 113.74M | 166.57M | 105.86M |
| Cost of Revenue | - | 65.45M | 73.83M | 35.01M | 61.28M | 46.09M |
| Gross Profit | - | 67.32M | 99.41M | 78.74M | 105.29M | 59.78M |
| Operating Expenses | - | 56.74M | 81.36M | 77.42M | 57.04M | 50.10M |
| Operating Income | - | 10.58M | 18.06M | 1.31M | 48.26M | 9.67M |
| EBITDA | - | 137.22M | 51.74M | 43.57M | 78.54M | 52.08M |
| Interest Expense | - | 35.54M | 33.53M | 39.38M | 28.42M | 40.81M |
| Pretax Income | - | 93.42M | 9.31M | -6.09M | 39.70M | 986.00K |
| Tax Provision | - | -16.26M | -22.73M | -835.00K | 148.25M | -44.00K |
| Net Income | - | 109.68M | 32.04M | -5.25M | -108.55M | 1.03M |
| Diluted EPS | - | 0.35 | - | - | - | 0.00 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 83.03M | 91.43M | 489.68M | 586.32M |
| Cost of Revenue | - | 64.09M | 160.86M | 185.31M | 235.56M |
| Gross Profit | - | 18.93M | -69.42M | 304.37M | 350.76M |
| Operating Expenses | - | 365.38M | 285.44M | 234.73M | 272.56M |
| Operating Income | - | -346.44M | -354.86M | 69.64M | 78.21M |
| EBITDA | - | -453.76M | -493.67M | -32.27M | 311.07M |
| Interest Expense | - | 77.47M | 133.17M | 153.99M | 136.87M |
| Pretax Income | - | -551.65M | -651.05M | -217.56M | 136.35M |
| Tax Provision | - | -38.07M | -99.32M | 14.30M | 108.43M |
| Net Income | - | -513.58M | -551.73M | -231.86M | 27.92M |
| Diluted EPS | - | -2.60 | -2.43 | -0.87 | 0.10 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 828.44M | 950.09M | 1.22B | 1.49B |
| Current Assets | - | 230.74M | 194.84M | 455.02M | 574.01M |
| Cash & Equivalents | - | 66.43M | 11.16M | 51.43M | 172.36M |
| Inventory | - | 71.47M | 74.43M | 127.89M | 220.05M |
| Receivables | - | 32.97M | 41.29M | 160.22M | 69.74M |
| Total Liabilities | - | 1.39B | 1.88B | 1.63B | 1.77B |
| Current Liabilities | - | 167.29M | 260.95M | 193.40M | 304.08M |
| Long Term Debt | - | 744.65M | 922.13M | 1.04B | 1.26B |
| Total Debt | - | 805.10M | 1.08B | 1.19B | 1.45B |
| Total Equity | - | -564.42M | -932.49M | -412.77M | -284.49M |
| Shares Outstanding | - | 248.65M | 289.73M | 324.80M | 334.04M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -312.39M | -312.19M | -236.84M | -50.20M |
| Investing Cash Flow | - | -63.54M | -46.34M | -18.87M | -104.22M |
| Financing Cash Flow | - | 424.91M | 301.32M | 297.31M | 270.83M |
| Capital Expenditure | - | -49.00M | -46.47M | -57.00M | -96.13M |
| Free Cash Flow | - | -361.39M | -358.66M | -293.84M | -146.33M |
| Net Change in Cash | - | 48.98M | -57.21M | 41.59M | 116.42M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 22.8% | -75.9% | 62.2% | 59.8% |
| Operating Margin % | - | -417.3% | -388.1% | 14.2% | 13.3% |
| Net Margin % | - | -618.6% | -603.4% | -47.3% | 4.8% |
| ROE % | - | 91.0% | 59.2% | 56.2% | -9.8% |
| ROCE % | - | -52.4% | -51.5% | 6.8% | 6.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALVO
Alvotech (ALVO) Could Be 72% Undervalued Following FDA Inspection Closure - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQVExJQ1JwSHMtY3ZJNFpZNFF4MC14bnVqNzNtc01IeFBuVjl0bDNzUmJESjFRNmZXSG9LNEdURVJ1cWdpYVBzazVBT3ZUS1gwVk1iVkdUMXNXcmpTWDNTYzkwSldydGc5aFZ6c2p0dUJqY19oY2ZfS2g3WHVtU3BESEd1SUhCMl9DYmpMOU…
Alvotech (NASDAQ:ALVO) Shares Down 6.7% - Time to Sell? - MarketBeat
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQQ0drUGR4aHJKNkFkR3Z5WDVUdWpEdzlYZFhlVkFyOVI4SzI0VUt6NnBKQ3hadF9aS25nNE1YWnN4QjlWb1Y4dHRRal9lN1lOMmpLRkQwcEpKTGpkdzFETzNOUGx0WVllU0FrUDZPSWJGaWlCTDBaZ01zTmVBTDBMZHlGVFF1czdtcWEzbH…
Alvotech (ALVO) Stock Analysis: Exploring a Potential 51.72% Upside in the Biosimilars Market - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNcTd0ZW1LMXNTdll5a1lrMUlLcGhLanJhSXBDN0YwQkJlc3YwVV94STMzaE5uekZfQWFxQ3lXVWVGYkFldDlCVXllR0E5ZmhhVHB5dW96NEw2LXJvWG1PTF93T0I4TVZqMUdNcWU3aE9xd1NxeDJGamtmZmtzZ0Q1UU9vUlc5Q2h0RF9PV3…
Alvotech (ALVO) Stock May Be Undervalued Following Its $125 Million Offering - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPTm5RUkFyeF9MSGVPazlSR2NzT1pIbVZoZkk1ZFVtRWwtYVFsMzJuYmt4TXVuckZYbEIwUFhRZElCWW84djJiRXR2ZHdJSndhdDgzTUNWMXNVaXlxUnQzUE8xb1E0cklDZkhldnJYWFZpVS1rR0JCc0tLRVZJY3FkVWQtS1g1MXltbW1LbG…
Alvotech works toward FDA approval for three biosimilar applications - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQUFhKOEswRnVhMXRtU1Q2R0xnQ3BzQmRyTkhJZlJSVmN5b2RJc3ROSi1aem5FNTE0bjVwTEN4cmhBR2hjRGlMcTVjVERMX25kR1lUZ05BWTNPS0paMlNpYW5tSU1qR2djR2ZBck55M3laanNOb0lGZXA3Xy03NUZyc0xsQzM1anN2UzRsYl…
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMijgJBVV95cUxQUDMzOFgxLTdwMkZ0T2R1UUx4bnVDVVRuS2dLOVRxQUpxTVhMT3o4SVE1dTdlZEd5S0h1OTE4M1V3dlpnbTR0UmtsUDhqb0RZYlZBLWFQYktLODJrZWVmc09NNGhsbHRod3VvMFZsaXp5UlROakh3QVB4bGtzV1ZxXzlURUFFUEFRZnJGWV…
ALVO — Frequently Asked Questions
What is the current share price of ALVO?
As of 2026-08-05 17:25 PDT, ALVO trades at $3.76 on NASDAQ/NYSE. Its 52-week range is $3.00 to $9.00.
What is the market capitalisation of ALVO?
ALVO has a market capitalisation of $1.26B on NASDAQ/NYSE.
What is the P/E ratio of ALVO?
ALVO trades at a trailing price-to-earnings (P/E) ratio of 37.60. Its price-to-book (P/B) ratio is -4.41.
What is the return on equity (ROE) of ALVO?
ALVO has a return on equity (ROE) of -9.81%. Its return on capital employed (ROCE) is 6.61%.
Is ALVO a good stock to buy?
This page provides a data-driven analysis of ALVO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.